Literature DB >> 12649384

Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.

Ai-Ming Yu1, Jeffrey R Idle, Kristopher W Krausz, Adrian Küpfer, Frank J Gonzalez.   

Abstract

The psychotropic beta-carboline alkaloids, showing high affinity for 5-hydroxytryptamine, dopamine, benzodiazepine, and imidazoline receptors and the stimulation of locus coeruleus neurons, are formed endogenously from tryptophan-derived indolealkylamines through the Pictet-Spengler condensation with aldehydes in both plants and mammals. Cytochromes P450 1A1 (18.5), 1A2 (20), and 2D6 (100) catalyzed the O-demethylation of harmaline, and CYP1A1 (98.5), CYP1A2 (35), CYP2C9 (16), CYP2C19 (30), and CYP2D6 (115) catalyzed that of harmine (relative activities). The dehydrogenation/aromatization of harmaline to harmine was not carried out by aromatase (CYP19), CYP1A2, CYP2C9, CYP2D6, CYP3A4, pooled recombinant cytochromes P450, or human liver microsomes (HLMs). Kinetic parameters were calculated for the O-demethylations mediated by each isozyme and by pooled HLMs. K(cat) (min(-1)) and K(m) Awake M) values for harmaline were: CYP1A1, 10.8 and 11.8; CYP1A2, 12.3 and 13.3; CYP2C9, 5.3 and 175; CYP2C19, 10.3 and 160; and CYP2D6, 39.9 and 1.4. Values for harmine were: CYP1A1, 45.2 and 52.2; CYP1A2, 9.2 and 14.7; CYP2C9, 11.9 and 117; CYP2C19, 21.4 and 121; and CYP2D6, 29.7 and 7.4. Inhibition studies using monoclonal antibodies confirmed that CYP1A2 and CYP2D6 were the major isozymes contributing to both harmaline (20% and 50%, respectively) and harmine (20% and 30%) O-demethylations in pooled HLMs. The turnover numbers for CYP2D6 are among the highest ever reported for a CYP2D6 substrate. Finally, CYP2D6-transgenic mice were found to have increased harmaline and harmine O-demethylase activities as compared with wild-type mice. These findings suggest a role for polymorphic CYP2D6 in the pharmacology and toxicology of harmine and harmaline.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649384     DOI: 10.1124/jpet.102.047050

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

1.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

2.  Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol.

Authors:  Mohamed A M El Gendy; Anatoly A Soshilov; Michael S Denison; Ayman O S El-Kadi
Journal:  Toxicol Lett       Date:  2011-10-06       Impact factor: 4.372

Review 3.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

4.  A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach.

Authors:  Chi Chen; Xiaochao Ma; Michael A Malfatti; Kristopher W Krausz; Shioko Kimura; James S Felton; Jeffrey R Idle; Frank J Gonzalez
Journal:  Chem Res Toxicol       Date:  2007-02-06       Impact factor: 3.739

5.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

6.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

7.  Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms.

Authors:  Mohamed A M El Gendy; Anatoly A Soshilov; Michael S Denison; Ayman O S El-Kadi
Journal:  Food Chem Toxicol       Date:  2011-10-21       Impact factor: 6.023

Review 8.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

9.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Authors:  Chao Wu; Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2009-05-13       Impact factor: 5.858

10.  The algal hepatoxoxin okadaic acid is a substrate for human cytochromes CYP3A4 and CYP3A5.

Authors:  Fujiang Guo; Tianying An; Kathleen S Rein
Journal:  Toxicon       Date:  2009-08-20       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.